Wednesday, February 7, 2018

(LML) WHO Goodwill Ambassador’s Newsletter Issue No. 88

Leprosy Mailing List – February 7,  2018

Ref.:  (LML) WHO Goodwill Ambassador's Newsletter Issue No. 88 

From:  Takahiro Nanri, Tokyo, Japan


 

Dear Dr Schreuder and Friends,

 

Warm greetings from Sasakawa Memorial Health Foundation in Tokyo. 

We have uploaded our latest edition of "WHO Goodwill Ambassador's Newsletter Issue No.88" on our website. Please visit http://www.smhf.or.jp/e/ambassador/index.html to obtain electronic version of this issue. 

In this issue we feature:

-       MESSAGE: 'Elimination Trauma'

-       REPORT: Stepping on the Accelerator

India looks to generate increased momentum against leprosy.

-       INTERVIEW: Gorontalo's To-Do List

In order to tackle leprosy, there is no getting around the issue of stigma.

-       LEPROSY WISH LIST

-       HUMAN STORY: Keep Your Spirits Up!

Al Qadri contracted leprosy as a boy. Now he has a message for everyone.

-       MEMO: Promoting Inclusion

WHO informal consultation looks at stopping discrimination, promoting inclusion.

-       MUSEUM PIECE: HIROKO HOLDING A CAT

-       AMBASSADOR'S JOURNAL: On-Air in Sulawesi

On his latest visit to Indonesia, the Goodwill Ambassador takes part in radio and TV phone-in programs as part of his mission to raise awareness of leprosy.

-       BACK TO UMBAKI

-       NEWS: Progress on NTDs

In 2016, more than 1 billion people were treated for at least one neglected tropical disease.

-       FROM THE EDITOR: WORDS TO LIVE BY

 

We hope you would enjoy reading our latest Newsletter!

 

 

Takahiro Nanri

Sasakawa Memorial Health Foundation

*********************************************************

Sasakawa Memorial Health Foundation

Tel:  03-6229-5377 

Fax: 03-6229-5388

email: smhf@tnfb.jp

visit our website at http://www.smhf.or.jp/

facebook  https://www.facebook.com/s


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


Tuesday, February 6, 2018

(LML) Reliability of global leprosy statistics

Leprosy Mailing List – February 6,  2018

Ref.:   (LML) Reliability of global leprosy statistics 

From:  Joel Almeida, London and Mumbai


Dear Pieter,

 

 

Thank you for the mail by Claudio Salgado "Reliability of Global Leprosy Statistics" of February 1, 2018.

 

A sample survey in Brazil (Amazon) found that 4% (95% c.i. +/-1%) of school children with a mean age of 13.3 years had clinical signs of leprosy (1). Almost 50% of school children had seropositivity for antibodies to the M.leprae-specific phenolic glycolipid-1. 

 

Such sample surveys performed by skilled clinicians seem more reliable than the numbers usually reported to WHO. Those serious about controlling leprosy and its disfiguring consequences might usefully use such sample surveys in their own localities. This can help generate political and public support with a consequent boost in financing.

 

The picture that typically emerges in endemic areas is of a population swimming in a sea of M. leprae.

 

Even door-to-door case detection campaigns by inexperienced personnel are likely to miss signs of leprosy while mistaking other signs for leprosy. Sample surveys performed by skilled clinicians are more reliable.

 

In the past, skilled clinicians in India have found that the vast majority of people with clinical signs were missed by inexperienced workers. The true incidence rate of clinical signs of leprosy may well be between 4 and 9 times that found by case detection campaigns using inexperienced workers.

 

The number of cases on the register is meaningless. It can be reduced to zero within one minute by a simple expedient: remove all cases from the register after the first dose of MDT. Then the point prevalence of registered cases will immediately become zero. In finance, there is a term for such practices: cooking the books. 

 

Unfortunately, some still rely on prevalence of cases on the register to declare a 90% or 99% reduction in leprosy. This is epidemiological nonsense in the context of shortened durations of MDT. Worse, it has been damaging on 3 fronts:

 

1) Less money for leprosy work

2) Less bright young talent coming into leprosy work

3) Less attention to protecting the nerves of people during and after MDT, with an increasing burden of permanent disfigurement.

 

Leprosy continues to infect children, and in India it has doubled the number of cases with visible deformity at diagnosis, since 2005-6..

 

In TB, the 1980s saw a premature declaration of victory with over-optimistic promises. In the 1990s I had the privilege to be part of Dr. Arata Kochi's team at WHO HQ. We put TB back on the global agenda, with an increase in financing from under 100 million USD per year to several billion USD/year now.

 

The first step was to decisively and firmly correct the mistaken notion that TB was declining, and that victory was imminent. The second was to draw attention to the impact of TB on human lives.

 

In leprosy, we are at the first mile of a marathon. We can attempt this journey blindfolded and spouting dubious claims, or we can do this with our eyes open and testing our claims with sample surveys carried out by skilled and experienced clinicians. 

 

Our Brazilian colleagues have set a good example, as have Indian colleagues who carry out sample surveys. May their example spread.

 

 

Joel Almeida

 

 

Reference

 

1. Josafá Gonçalves Barreto; Layana de Souza Guimarães; Marco Andrey Cipriani Frade; Patricia Sammarco Rosa; Claudio Guedes Salgado. High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region. Mem. Inst. Oswaldo Cruz vol.107  supl.1 Rio de Janeiro Dec. 2012

ht


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

 


Monday, February 5, 2018

(LML) Request for advice on HIV and Leprosy

Leprosy Mailing List – February 5,  2018

Ref.:   (LML)  Request for advice on HIV and Leprosy

From:  Joseph Kawuma, Kampala, Uganda


 

Dear Pieter,

 

I guess that for purposes of responding to the request from Dr. Tahir (LML, January 22, 2018), it would be important to know if the patient was on anti-retroviral therapy (ART) and if so, what the actual treatment was and how it was related (in sequence) to the occurrence of the presented clinical picture.

 

 

Best wishes

 

H Joseph Kawuma,

Uganda


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


Saturday, February 3, 2018

(LML) Mortality in leprosy

 

Leprosy Mailing List – February 3,  2018

Ref.:      (LML) Mortality in leprosy

From:  Diana Lockwood, London, UK


 

Dear Pieter,

 

Thank Arry Pongtiku (LML, January 26, 2018) for opening this discussion. It was good to have the contribution by Dr Shimelis (LML, January 29, 2018) on the mortality they found in Ethiopia with ENL. Mortality in leprosy is underappreciated and often only recognised in trials when we have to account for all the patient outcomes.  I think that mortality in leprosy is associated with the drugs that we use to treat leprosy, mainly dapsone and also mortality associated with steroid treatment in leprosy for reactions.  ENL can also cause death and we have found this in both Brazil and Ethiopia. We found several deaths in our AZALEP study and both Dapsone and azathioprine may have played a role here.1

Dapsone causes anaemia and sometimes agranulocytosis. It also causes dapsone hypersensivity syndrome which is associated with deaths reported from Nepal2 and China3.  The topic has also been addressed with a systematic review which showed that most of the Dapsone deaths reported were associated with leprosy treatment.4 the death rate was 9.9%.  Fatal agranulocytosis has been reported after treatment for tuberculoid leprosy in Sri Lanka. 5 and Brazil.6 We probably need to be more careful in chasing up patients who have not attended. We also need to monitor haemoglobin more closely in patients who are on MDT.

Mortality also occurs from the complications of neuropathy such as chronic osteomyelitis.

Suicide is another under recognised cause of death. This has been recognised earlier as a complication of ENL because of the recurrent debilitating episodes of inflammation. It may also occur as part of the stigma associated with leprosy.

This is a very important area that we need to spend more effort on.

 

Diana NJ Lockwood

Professor of Tropical Medicine, London School of Hygiene & Tropical Medicine.

London

 

1.         Lockwood DN, Darlong J, Govindharaj P, Kurian R, Sundarrao P, John AS. AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. PLoS Negl Trop Dis. 2017 Mar;11(3):e0005348

2.         Pandey B, Shrestha K, Lewis J, Hawksworth RA, Walker SL. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal. Trop Doct. 2007 Jul;37(3):162-3

3.         Shen J, Yan L, Yu M, Li J, Yu X, Zhang G. Six years' follow-up of multibacillary leprosy patients treated with uniform multi-drug therapy in China. Int J Dermatol. 2015 Mar;54(3):315-8

4.         Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol. 2012 Mar;92(2):194-9

5.         Satarasinghe RL, Jayawardana MA, De Silva GV, Murugathas S, Riyaaz AA, Wickrmasingha UD, et al. Total agranulocytosis caused by dapsone therapy for tuberculoid leprosy--an unappreciated serious side effect of anti-leprosy treatment with clinical implications. Drug Metabol Drug Interact. 2009;24(2-4):325-9

6.         Silva IM, Oliveira CA, Guedes WR, Oliveira BB, Oliveira DA, Guedes Filho G. Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report. Braz J Infect Dis. 2009 Apr;13(2):158-60


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


(LML) Chemoprophylaxis in Leprosy

Leprosy Mailing List – February 3,  2018

Ref.:    (LML) Chemoprophylaxis in Leprosy

From:  Diana Lockwood, London, UK


 

Dear Pieter,

 

Regarding the risk of inducing resistance in Mycobacterium tuberculosis with SDR prophylaxis, I would like to thank Wim (LML, January 27, 2018) for posting the article from Infectious Disease of Poverty.1  This is a commentary by a group of experts.  The article is a description of what happens when people have TB and TB treatment. What is needed is a data-based analysis of the numbers of patients being treated for TB in countries with proposed roll out of single dose Rifampicin (SDR) as PEP. This should include modelling of the numbers of extra doses of Rifampicin that will need to be given in these settings. This will be millions of doses of Rifampicin because of the numbers of people involved when household contacts are treated.  Then the risk of Rifampicin resistance can be calculated. This level of opinion rates as a grade 3 using the Oxford level of evidence criteria.2

 1.        Mieras L, Anthony R, van Brakel W, Bratschi MW, van den Broek J, Cambau E, et al. Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infect Dis Poverty. 2016 Jun 8;5(1):46

2. https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf

 

Best Wishes

Diana Lockwood

Professor of Tropical Medicine,

London School of Hygiene and Tropical Medicine

 

(Note editor: there is a possibility that my computer has been hacked. Be aware of phishing mails!)


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 


Friday, February 2, 2018

(LML) Request for advice on HIV and Leprosy

Leprosy Mailing List – February 2,  2018

Ref.:   (LML)  Request for advice on HIV and Leprosy

From:  Diana Lockwood, London, UK


 

Dear Pieter

I have a comment to add to the discussion on HIV and Leprosy (Tahir Dairu, LML January 22, 2018). Like suggested by colleagues, this patient may be experiencing a leprosy reaction. We have found a very high rate of leprosy reactions in patients with HIV co-infection. 12  This might be causing the itchiness in the skin lesions.

1.         Deps P, Lucas S, Porro AM, Maeda SM, Tomimori J, Guidella C, et al. Clinical and histological features of leprosy and human immunodeficiency virus co-infection in Brazil. Clin Exp Dermatol. 2013 Jul;38(5):470-7

2.         Lockwood DN, Lambert SM. Human immunodeficiency virus and leprosy: an update. Dermatol Clin. 2011 Jan;29(1):125-8

 

Diana NJ Lockwood


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com


Thursday, February 1, 2018

LML) Reliability of global leprosy statistics

Leprosy Mailing List – February 1,  2018

Ref.:  LML) Reliability of global leprosy statistics 

From:  Claudio Salgado, Ribeirão Preto, Brazil


Note editor: this message has been sent earlier, but not apparently not received by everyone!

 

Dear Pieter,


Could you share our comment published on The Lancet Infectious Diseases with the leprosy mailing list participants? We discussed the last leprosy numbers made available by WHO on 2017. Are leprosy case numbers truly reliable?

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2818%2930012-4/fulltext#.WmqavNG5KVI.email

 

Thanks,

 

Claudio

 

Note editor: I would like to refer to an editorial in Leprosy Review by P.E.M. Fine "Global Leprosy Statistics: a cause of pride, or frustration?" Lepr Rev (2006) 77,295-297


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com